-
Company Insights
Kingfisher – Digital Transformation Strategies
Kingfisher Digital Transformation Strategies Overview Kingfisher has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Kingfisher was estimated at $369.9 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Kingfisher sells home improvement products and offers home improvement services to consumers and trade professionals in eight European countries. It operates under the B&Q,...
-
Product Insights
Spinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Analyst Opinions
Top Trends in Foodservice – Industry Insights
Reasons to buy the ‘Top Trends in Foodservice’ industry insight report: Analyze the global foodservice trends to understand the market better. Understand the key market players, foodservice operators, consumer needs, and behavior within the foodservice industry. Examine the trends explored in this research report including off-premise dining, social media-driven menus, adult beverage innovation, and tackling food waste. Explore the key trends that foodservice operators can tap to succeed in the foodservice market. How is our ‘Top Trends in Foodservice’ report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Metastatic Pancreatic Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Endometrial Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Uterine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Uterine Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Fallopian Tube Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Gastroesophageal (GE) Junction Carcinomas Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Epithelial Ovarian Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Peritoneal Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...